2 insiders at Artiva Biotherapeutics, Inc. (ARTV) reported open-market stock purchases totaling $109,178,445 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from RA CAPITAL MANAGEMENT, L.P. (director, 10 percent owner: ), who acquired 152,472 shares at $8.93 on July 16, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-07-31 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 24,944 | $9.93 | $247,694 | SEC Form 4 |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 20,824 | $9.99 | $208,032 | SEC Form 4 |
| 2026-07-24 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 41,319 | $9.99 | $412,777 | SEC Form 4 |
| 2026-07-23 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 59,880 | $9.96 | $596,405 | SEC Form 4 |
| 2026-07-22 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 84,124 | $9.93 | $835,351 | SEC Form 4 |
| 2026-07-21 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 120,582 | $9.55 | $1,151,558 | SEC Form 4 |
| 2026-07-17 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 7,882 | $8.95 | $70,544 | SEC Form 4 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 152,472 | $8.93 | $1,361,575 | SEC Form 4 |
| 2026-07-13 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 6,522 | $8.94 | $58,307 | SEC Form 4 |
| 2026-07-13 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 6,552 | $8.94 | $58,575 | SEC Form 4 |
| 2026-07-10 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 15,102 | $8.97 | $135,465 | SEC Form 4 |
| 2026-06-26 | RA CAPITAL MANAGEMENT, L.P. | director, 10 percent owner: | 1,876 | $8.98 | $16,846 | SEC Form 4 |
Artiva Biotherapeutics, Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $576M, with shares trading near $11.78.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.